0001654954-22-011096.txt : 20220812 0001654954-22-011096.hdr.sgml : 20220812 20220812060136 ACCESSION NUMBER: 0001654954-22-011096 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220809 FILED AS OF DATE: 20220812 DATE AS OF CHANGE: 20220812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wu Hui-Lan CENTRAL INDEX KEY: 0001901988 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41461 FILM NUMBER: 221157649 MAIL ADDRESS: STREET 1: 8880 RIO SAN DIEGO DRIVE STREET 2: SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 858-869-2986 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 4 1 section16.xml PRIMARY DOCUMENT X0306 4 2022-08-09 0001014763 Ainos, Inc. AIMD 0001901988 Wu Hui-Lan 8880 RIO SAN DIEGO DRIVE, SUITE 800 SAN DIEGO CA 92108 false true false false Chief Financial Officer Common Stock 2022-08-09 4 A false 14705 3.40 A 18905 I Daughter Common Stock 11200 D RSU 2022-07-28 4 A false 2000000 .01 A 2022-09-30 2022-09-30 Common Stock 2000000 2000000 D Yun-Huan Liao is Hui-Lan Wu's daughter Reference is made to that certain Convertible Note Purchase Agreement and Convertible Promissory Note ("Note") in the principal amount of $50,000 between the Issuer and the Reporting Person's daughter, Yun-Han Liao. The Note bears no interest, matures on March 30, 2027, and is subject to mandatory conversion at a conversion price of 80% of an initial property offering price (if the Issuer conducts an initial public offering). On 08/11/22, the Company completed a public offering at a $4.25 per unit price ("Offering") and a 15-for-1 reverse stock split on 08/08/22 ("Reverse Split"). Transaction reflects an acquisition price of $3.40 per share (80% of the Offering) and the issued shares give effect to the Reverse Split. Reference is made to the Restricted Stock Units (the "RSU") granted pursuant to an employment Mandate Agreement dated March 17, 2022 (the "Mandate Agreement") under the Company's 2021 Stock Incentive Plan. Each RSU represents a right to receive one (1) share of common stock upon vesting and the expiration of any applicable restricted period, or in the sole discretion of the Compensation Committee, the cash value thereof (or any combination thereof). Holders of RSUs have no rights or privileges as a stockholder. The shares underlying the RSUs will vest on September 30, 2022 and are may not be sold within 6 months of the grant date. Prior to the Reverse Split discussed herein the Reporting Person beneficially owned 168,000 shares of common stock of the Issuer and after the Reverse Split, the Reporting Person owned 11,200 common stock. Prior to the Reverse Split discussed herein the Reporting Person beneficially owned 63,000 shares of common stock of the Issuer and after the Reverse Split, and prior to the present issuances, 4,200 common stock. The amounts of securities beneficially owned in column 5 of this report is calculated from a post-split baseline of 4,200. /s/ John Junyong Lee POA for Hui-Lan Wu 2022-08-11